BioMS expands multiple sclerosis trial for MBP8298

By Jennifer Chiou

New York, March 13 - BioMS Medical Corp. announced the expansion of the clinical development program for its lead drug candidate, MBP8298, a synthetic peptide therapeutic.

Under the additional work, BioMS will begin a clinical trial for MBP8298 in relapsing-remitting MS patients in the second half of 2006.

"We have good scientific rationale to believe that MBP8298 has the potential to provide a benefit to MS patients at any stage of the disease," president and chief executive officer Kevin Giese said in a news release.

The company said the drug is already in international phase 2/3 clinical trials with secondary progressive multiple sclerosis patients.

BioMS also noted it will present the results of an MBP8298 study at the 58th Annual Meeting of the American Academy of Neurology on April 4 in San Diego.

On Dec. 6, the company announced it received 38 additional patents for MBP8298, raising the number of granted patents to 88.

The Edmonton, Alta., biotechnology company has an equity interest in BioCyDex, a private company developing technology for the delivery of drugs into cells.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.